Company intelligence / Profile preview

Bio-Medisinsk Innovasjon AS

Oslo, Norwaybmioslo.no ↗
Ownership
Private
Development stage
Other
01

Overview

In 2007, the company completed a Phase II clinical study investigating the effect of piboserod in patients with chronic heart failure[4]

Therapeutic areas
GastroenterologyCardiovascular
Modalities
Small molecules (piboserod)
Industry
Investors
02

Partnerships

Medinnova (TTO for several leading hospitals)[1]

Beyond the preview

Go deeper on Bio-Medisinsk Innovasjon AS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-Medisinsk Innovasjon AS.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call